Literature DB >> 12100156

Blast crisis of Philadelphia chromosome-positive chronic myeloid leukaemia carrying micro-bcr breakpoint (e19a2 and e191a).

Akimichi Ohsaka1, Shigeru Hoshino, Masaru Kobayashi, Hideyuki Kudo, Ryuji Kawaguchi.   

Abstract

We describe two Philadelphia chromosome-positive chronic myeloid leukaemia (Ph-positive CML) patients carrying micro-bcr (micro-bcr) breakpoint, who developed blast crisis within 5 years of diagnosis. Reverse transcription polymerase chain reaction analysis of bone marrow cells using primers specific for the p210BCR-ABL fusion transcript showed aberrant large-sized bands in both cases (986 bp in patient 1 and 1031 bp in patient 2). Sequencing analysis of these products revealed BCR-ABL fusion transcripts with e19a2 in patient 1 and e191a in patient 2. These findings suggest that CML carrying micro-bcr breakpoint may exhibit a similar clinical course to classical CML, and that it may not be a mild form of the disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12100156     DOI: 10.1046/j.1365-2141.2002.03570.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Early Complete Molecular Response to First-Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230 Transcript.

Authors:  Marianna Greco; Giovanni Caocci; Giorgio La Nasa
Journal:  Case Rep Hematol       Date:  2013-07-11

2.  Rapid Evolution to Blast Crisis Associated with a Q252H ABL1 Kinase Domain Mutation in e19a2 BCR-ABL1 Chronic Myeloid Leukaemia.

Authors:  Sarah L McCarron; Karena Maher; Johanna Kelly; Mary F Ryan; Stephen E Langabeer
Journal:  Case Rep Hematol       Date:  2013-09-16

Review 3.  Nilotinib for the Frontline Treatment of Chronic Myeloid Leukemia Carrying the p230 Transcript: Dream or Reality?

Authors:  Maurizio Capuozzo; Alessandro Ottaiano; Eduardo Nava; Stefania Cascone; Claudia Cinque; Adriano Vercellone; Corinne Scognamiglio; Emilia Palumbo; Rosario V Iaffaioli
Journal:  Front Oncol       Date:  2014-02-03       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.